Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) EBITDA (2016 - 2025)

Editas Medicine (EDIT) has disclosed EBITDA for 11 consecutive years, with -$24.5 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA rose 62.62% to -$24.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$198.8 million, a 12.99% increase, with the full-year FY2024 number at -$251.2 million, down 48.45% from a year prior.
  • EBITDA was -$24.5 million for Q3 2025 at Editas Medicine, up from -$51.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$24.0 million in Q4 2023 to a low of -$76.2 million in Q1 2025.
  • A 5-year average of -$52.2 million and a median of -$51.5 million in 2025 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: crashed 536.73% in 2021, then soared 62.62% in 2025.
  • Editas Medicine's EBITDA stood at -$41.6 million in 2021, then tumbled by 52.48% to -$63.4 million in 2022, then surged by 62.23% to -$24.0 million in 2023, then tumbled by 94.44% to -$46.6 million in 2024, then surged by 47.31% to -$24.5 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's EBITDA are -$24.5 million (Q3 2025), -$51.5 million (Q2 2025), and -$76.2 million (Q1 2025).